Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · GRAIL, Inc. (GRAL)

GRAIL Q2 revenue rises 26% to $44.7 million; net loss narrows to $110.2 million

Positive Impact 3 of 5 earnings Written later

GRAIL reported second-quarter 2026 results, with total revenue up 26% year over year to $44.7 million and Galleri test revenue up 24% to $42.6 million. Net loss narrowed slightly to $110.2 million, but adjusted EBITDA loss widened to $90.3 million, and the company said it anticipates an FDA advisory committee in the fall for its Galleri PMA application.

Key points

  • Total revenue rose 26% to $44.7 million; Galleri test volume grew 35% to more than 61,000 in the quarter.
  • Net loss was $110.2 million versus $114.0 million a year earlier; gross loss narrowed 29% to $12.6 million.
  • Adjusted EBITDA loss was $90.3 million, up $11.9 million (15%) from the prior-year quarter.
  • Cash, cash equivalents and short-term marketable securities totaled $861.6 million as of June 30, 2026.

The filing

CompanyGRAIL, Inc. (GRAL)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:08 PM ET
Accession number0001628280-26-053341

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.